Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine
A universal influenza vaccine that does not require annual reformulation would have clear advantages over the currently approved seasonal vaccine. In this study, we combined the mucosal adjuvant alpha-galactosylceramide (αGalCer) and peptides designed across the highly conserved influenza precursor...
Gespeichert in:
| Veröffentlicht in: | Journal of general virology 2011-05, Vol.92 (Pt 5), p.1152-1161 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1161 |
|---|---|
| container_issue | Pt 5 |
| container_start_page | 1152 |
| container_title | Journal of general virology |
| container_volume | 92 |
| creator | MILLER, Darren S FINNIE, John BOWDEN, Timothy R SCHOLZ, Anita C OH, Sawyin KOK, Tuckweng BURRELL, Christopher J TRINIDAD, Lee BOYLE, David B PENG LI |
| description | A universal influenza vaccine that does not require annual reformulation would have clear advantages over the currently approved seasonal vaccine. In this study, we combined the mucosal adjuvant alpha-galactosylceramide (αGalCer) and peptides designed across the highly conserved influenza precursor haemagglutinin (HA(0)) cleavage loop as a vaccine. Peptides designed across the HA(0) of influenza A/H3N2 viruses, delivered to mice via the intranasal route with αGalCer as an adjuvant, provided 100 % protection following H3N2 virus challenge. Similarly, intranasal inoculation of peptides across the HA(0) of influenza A/H5N1 with αGalCer completely protected mice against heterotypic challenge with H3N2 virus. Our data suggest that these peptide vaccines effectively inhibited subsequent influenza A/H3N2 virus replication. In contrast, only 20 % of mice vaccinated with αGalCer-adjuvanted peptides spanning the HA(0) of H5N1 survived homologous viral challenge, possibly because the HA(0) of this virus subtype is cleaved by intracellular furin-like enzymes. Results of these studies demonstrated that HA(0) peptides adjuvanted with αGalCer have the potential to form the basis of a synthetic, intranasal influenza vaccine. |
| doi_str_mv | 10.1099/vir.0.028985-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_862287662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>862287662</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-b009b904f962bbdbcf6a4ebe81f955d87094a7fe29e6bd4b793a752f8d3dff0b3</originalsourceid><addsrcrecordid>eNpFkEtPGzEURq0KVAJ022XlDWI16bXH8_AyilpAikQXsLZsz3XqypkZ7JlI4dfjKgEkS3fhc77FIeQ7gyUDKX_ufVzCEngr26qAL2TBRF0VPH-dkQUA5wUrWXNBLlP6B8CEqJqv5IKzLLAaFiT-iWiD773VgaJz-doDTdPceUx0cNT3LszYv2q6on817vR2G-YpCz0dszrHNERqA-q93iINwzDSEcfJd1nX-dFxmLCffJ7fa2t9j9fk3OmQ8NvpXpHn37-e1vfF5vHuYb3aFFaUMBUGQBoJwsmaG9MZ62ot0GDLnKyqrm1ACt045BJr0wnTyFI3FXdtV3bOgSmvyO1xd4zDy4xpUjufLIagexzmpNqa87apa57J5ZG0cUgpolNj9DsdD4qB-p9Z5cwK1DGzgiz8OE3PZofdB_7eNQM3J0CnXNZF3VufPjnBOBcgyjcbQoi-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>862287662</pqid></control><display><type>article</type><title>Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine</title><source>MEDLINE</source><source>Microbiology Society</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>MILLER, Darren S ; FINNIE, John ; BOWDEN, Timothy R ; SCHOLZ, Anita C ; OH, Sawyin ; KOK, Tuckweng ; BURRELL, Christopher J ; TRINIDAD, Lee ; BOYLE, David B ; PENG LI</creator><creatorcontrib>MILLER, Darren S ; FINNIE, John ; BOWDEN, Timothy R ; SCHOLZ, Anita C ; OH, Sawyin ; KOK, Tuckweng ; BURRELL, Christopher J ; TRINIDAD, Lee ; BOYLE, David B ; PENG LI</creatorcontrib><description>A universal influenza vaccine that does not require annual reformulation would have clear advantages over the currently approved seasonal vaccine. In this study, we combined the mucosal adjuvant alpha-galactosylceramide (αGalCer) and peptides designed across the highly conserved influenza precursor haemagglutinin (HA(0)) cleavage loop as a vaccine. Peptides designed across the HA(0) of influenza A/H3N2 viruses, delivered to mice via the intranasal route with αGalCer as an adjuvant, provided 100 % protection following H3N2 virus challenge. Similarly, intranasal inoculation of peptides across the HA(0) of influenza A/H5N1 with αGalCer completely protected mice against heterotypic challenge with H3N2 virus. Our data suggest that these peptide vaccines effectively inhibited subsequent influenza A/H3N2 virus replication. In contrast, only 20 % of mice vaccinated with αGalCer-adjuvanted peptides spanning the HA(0) of H5N1 survived homologous viral challenge, possibly because the HA(0) of this virus subtype is cleaved by intracellular furin-like enzymes. Results of these studies demonstrated that HA(0) peptides adjuvanted with αGalCer have the potential to form the basis of a synthetic, intranasal influenza vaccine.</description><identifier>ISSN: 0022-1317</identifier><identifier>EISSN: 1465-2099</identifier><identifier>DOI: 10.1099/vir.0.028985-0</identifier><identifier>PMID: 21289160</identifier><identifier>CODEN: JGVIAY</identifier><language>eng</language><publisher>Reading: Society for General Microbiology</publisher><subject><![CDATA[Adjuvants, Immunologic - administration & dosage ; Animals ; Biological and medical sciences ; Body Weight ; Cross Protection ; Female ; Fundamental and applied biological sciences. Psychology ; Galactosylceramides - administration & dosage ; Hemagglutinin Glycoproteins, Influenza Virus - administration & dosage ; Hemagglutinin Glycoproteins, Influenza Virus - immunology ; Histocytochemistry ; Influenza A Virus, H3N2 Subtype - genetics ; Influenza A Virus, H3N2 Subtype - immunology ; Influenza A Virus, H5N1 Subtype - genetics ; Influenza A Virus, H5N1 Subtype - immunology ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - immunology ; Lung - pathology ; Lung - virology ; Mice ; Mice, Inbred BALB C ; Microbiology ; Microscopy ; Miscellaneous ; Orthomyxoviridae Infections - pathology ; Orthomyxoviridae Infections - prevention & control ; Protein Precursors - genetics ; Protein Precursors - metabolism ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Subunit - administration & dosage ; Vaccines, Subunit - immunology ; Viral Load ; Virology]]></subject><ispartof>Journal of general virology, 2011-05, Vol.92 (Pt 5), p.1152-1161</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-b009b904f962bbdbcf6a4ebe81f955d87094a7fe29e6bd4b793a752f8d3dff0b3</citedby><cites>FETCH-LOGICAL-c430t-b009b904f962bbdbcf6a4ebe81f955d87094a7fe29e6bd4b793a752f8d3dff0b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3733,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24122404$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21289160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MILLER, Darren S</creatorcontrib><creatorcontrib>FINNIE, John</creatorcontrib><creatorcontrib>BOWDEN, Timothy R</creatorcontrib><creatorcontrib>SCHOLZ, Anita C</creatorcontrib><creatorcontrib>OH, Sawyin</creatorcontrib><creatorcontrib>KOK, Tuckweng</creatorcontrib><creatorcontrib>BURRELL, Christopher J</creatorcontrib><creatorcontrib>TRINIDAD, Lee</creatorcontrib><creatorcontrib>BOYLE, David B</creatorcontrib><creatorcontrib>PENG LI</creatorcontrib><title>Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine</title><title>Journal of general virology</title><addtitle>J Gen Virol</addtitle><description>A universal influenza vaccine that does not require annual reformulation would have clear advantages over the currently approved seasonal vaccine. In this study, we combined the mucosal adjuvant alpha-galactosylceramide (αGalCer) and peptides designed across the highly conserved influenza precursor haemagglutinin (HA(0)) cleavage loop as a vaccine. Peptides designed across the HA(0) of influenza A/H3N2 viruses, delivered to mice via the intranasal route with αGalCer as an adjuvant, provided 100 % protection following H3N2 virus challenge. Similarly, intranasal inoculation of peptides across the HA(0) of influenza A/H5N1 with αGalCer completely protected mice against heterotypic challenge with H3N2 virus. Our data suggest that these peptide vaccines effectively inhibited subsequent influenza A/H3N2 virus replication. In contrast, only 20 % of mice vaccinated with αGalCer-adjuvanted peptides spanning the HA(0) of H5N1 survived homologous viral challenge, possibly because the HA(0) of this virus subtype is cleaved by intracellular furin-like enzymes. Results of these studies demonstrated that HA(0) peptides adjuvanted with αGalCer have the potential to form the basis of a synthetic, intranasal influenza vaccine.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Body Weight</subject><subject>Cross Protection</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Galactosylceramides - administration & dosage</subject><subject>Hemagglutinin Glycoproteins, Influenza Virus - administration & dosage</subject><subject>Hemagglutinin Glycoproteins, Influenza Virus - immunology</subject><subject>Histocytochemistry</subject><subject>Influenza A Virus, H3N2 Subtype - genetics</subject><subject>Influenza A Virus, H3N2 Subtype - immunology</subject><subject>Influenza A Virus, H5N1 Subtype - genetics</subject><subject>Influenza A Virus, H5N1 Subtype - immunology</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - immunology</subject><subject>Lung - pathology</subject><subject>Lung - virology</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Microbiology</subject><subject>Microscopy</subject><subject>Miscellaneous</subject><subject>Orthomyxoviridae Infections - pathology</subject><subject>Orthomyxoviridae Infections - prevention & control</subject><subject>Protein Precursors - genetics</subject><subject>Protein Precursors - metabolism</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Subunit - administration & dosage</subject><subject>Vaccines, Subunit - immunology</subject><subject>Viral Load</subject><subject>Virology</subject><issn>0022-1317</issn><issn>1465-2099</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtPGzEURq0KVAJ022XlDWI16bXH8_AyilpAikQXsLZsz3XqypkZ7JlI4dfjKgEkS3fhc77FIeQ7gyUDKX_ufVzCEngr26qAL2TBRF0VPH-dkQUA5wUrWXNBLlP6B8CEqJqv5IKzLLAaFiT-iWiD773VgaJz-doDTdPceUx0cNT3LszYv2q6on817vR2G-YpCz0dszrHNERqA-q93iINwzDSEcfJd1nX-dFxmLCffJ7fa2t9j9fk3OmQ8NvpXpHn37-e1vfF5vHuYb3aFFaUMBUGQBoJwsmaG9MZ62ot0GDLnKyqrm1ACt045BJr0wnTyFI3FXdtV3bOgSmvyO1xd4zDy4xpUjufLIagexzmpNqa87apa57J5ZG0cUgpolNj9DsdD4qB-p9Z5cwK1DGzgiz8OE3PZofdB_7eNQM3J0CnXNZF3VufPjnBOBcgyjcbQoi-</recordid><startdate>20110501</startdate><enddate>20110501</enddate><creator>MILLER, Darren S</creator><creator>FINNIE, John</creator><creator>BOWDEN, Timothy R</creator><creator>SCHOLZ, Anita C</creator><creator>OH, Sawyin</creator><creator>KOK, Tuckweng</creator><creator>BURRELL, Christopher J</creator><creator>TRINIDAD, Lee</creator><creator>BOYLE, David B</creator><creator>PENG LI</creator><general>Society for General Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110501</creationdate><title>Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine</title><author>MILLER, Darren S ; FINNIE, John ; BOWDEN, Timothy R ; SCHOLZ, Anita C ; OH, Sawyin ; KOK, Tuckweng ; BURRELL, Christopher J ; TRINIDAD, Lee ; BOYLE, David B ; PENG LI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-b009b904f962bbdbcf6a4ebe81f955d87094a7fe29e6bd4b793a752f8d3dff0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Body Weight</topic><topic>Cross Protection</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Galactosylceramides - administration & dosage</topic><topic>Hemagglutinin Glycoproteins, Influenza Virus - administration & dosage</topic><topic>Hemagglutinin Glycoproteins, Influenza Virus - immunology</topic><topic>Histocytochemistry</topic><topic>Influenza A Virus, H3N2 Subtype - genetics</topic><topic>Influenza A Virus, H3N2 Subtype - immunology</topic><topic>Influenza A Virus, H5N1 Subtype - genetics</topic><topic>Influenza A Virus, H5N1 Subtype - immunology</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - immunology</topic><topic>Lung - pathology</topic><topic>Lung - virology</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Microbiology</topic><topic>Microscopy</topic><topic>Miscellaneous</topic><topic>Orthomyxoviridae Infections - pathology</topic><topic>Orthomyxoviridae Infections - prevention & control</topic><topic>Protein Precursors - genetics</topic><topic>Protein Precursors - metabolism</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Subunit - administration & dosage</topic><topic>Vaccines, Subunit - immunology</topic><topic>Viral Load</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MILLER, Darren S</creatorcontrib><creatorcontrib>FINNIE, John</creatorcontrib><creatorcontrib>BOWDEN, Timothy R</creatorcontrib><creatorcontrib>SCHOLZ, Anita C</creatorcontrib><creatorcontrib>OH, Sawyin</creatorcontrib><creatorcontrib>KOK, Tuckweng</creatorcontrib><creatorcontrib>BURRELL, Christopher J</creatorcontrib><creatorcontrib>TRINIDAD, Lee</creatorcontrib><creatorcontrib>BOYLE, David B</creatorcontrib><creatorcontrib>PENG LI</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of general virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MILLER, Darren S</au><au>FINNIE, John</au><au>BOWDEN, Timothy R</au><au>SCHOLZ, Anita C</au><au>OH, Sawyin</au><au>KOK, Tuckweng</au><au>BURRELL, Christopher J</au><au>TRINIDAD, Lee</au><au>BOYLE, David B</au><au>PENG LI</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine</atitle><jtitle>Journal of general virology</jtitle><addtitle>J Gen Virol</addtitle><date>2011-05-01</date><risdate>2011</risdate><volume>92</volume><issue>Pt 5</issue><spage>1152</spage><epage>1161</epage><pages>1152-1161</pages><issn>0022-1317</issn><eissn>1465-2099</eissn><coden>JGVIAY</coden><abstract>A universal influenza vaccine that does not require annual reformulation would have clear advantages over the currently approved seasonal vaccine. In this study, we combined the mucosal adjuvant alpha-galactosylceramide (αGalCer) and peptides designed across the highly conserved influenza precursor haemagglutinin (HA(0)) cleavage loop as a vaccine. Peptides designed across the HA(0) of influenza A/H3N2 viruses, delivered to mice via the intranasal route with αGalCer as an adjuvant, provided 100 % protection following H3N2 virus challenge. Similarly, intranasal inoculation of peptides across the HA(0) of influenza A/H5N1 with αGalCer completely protected mice against heterotypic challenge with H3N2 virus. Our data suggest that these peptide vaccines effectively inhibited subsequent influenza A/H3N2 virus replication. In contrast, only 20 % of mice vaccinated with αGalCer-adjuvanted peptides spanning the HA(0) of H5N1 survived homologous viral challenge, possibly because the HA(0) of this virus subtype is cleaved by intracellular furin-like enzymes. Results of these studies demonstrated that HA(0) peptides adjuvanted with αGalCer have the potential to form the basis of a synthetic, intranasal influenza vaccine.</abstract><cop>Reading</cop><pub>Society for General Microbiology</pub><pmid>21289160</pmid><doi>10.1099/vir.0.028985-0</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1317 |
| ispartof | Journal of general virology, 2011-05, Vol.92 (Pt 5), p.1152-1161 |
| issn | 0022-1317 1465-2099 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_862287662 |
| source | MEDLINE; Microbiology Society; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adjuvants, Immunologic - administration & dosage Animals Biological and medical sciences Body Weight Cross Protection Female Fundamental and applied biological sciences. Psychology Galactosylceramides - administration & dosage Hemagglutinin Glycoproteins, Influenza Virus - administration & dosage Hemagglutinin Glycoproteins, Influenza Virus - immunology Histocytochemistry Influenza A Virus, H3N2 Subtype - genetics Influenza A Virus, H3N2 Subtype - immunology Influenza A Virus, H5N1 Subtype - genetics Influenza A Virus, H5N1 Subtype - immunology Influenza Vaccines - administration & dosage Influenza Vaccines - immunology Lung - pathology Lung - virology Mice Mice, Inbred BALB C Microbiology Microscopy Miscellaneous Orthomyxoviridae Infections - pathology Orthomyxoviridae Infections - prevention & control Protein Precursors - genetics Protein Precursors - metabolism Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Subunit - administration & dosage Vaccines, Subunit - immunology Viral Load Virology |
| title | Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T02%3A13%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preclinical%20efficacy%20studies%20of%20influenza%20A%20haemagglutinin%20precursor%20cleavage%20loop%20peptides%20as%20a%20potential%20vaccine&rft.jtitle=Journal%20of%20general%20virology&rft.au=MILLER,%20Darren%20S&rft.date=2011-05-01&rft.volume=92&rft.issue=Pt%205&rft.spage=1152&rft.epage=1161&rft.pages=1152-1161&rft.issn=0022-1317&rft.eissn=1465-2099&rft.coden=JGVIAY&rft_id=info:doi/10.1099/vir.0.028985-0&rft_dat=%3Cproquest_cross%3E862287662%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=862287662&rft_id=info:pmid/21289160&rfr_iscdi=true |